NCT02391519 Effects of High Altitude on AMPK Activation
| NCT ID | NCT02391519 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Pregnancy |
| Study Type | OBSERVATIONAL |
| Enrollment | 84 participants |
| Start Date | 2016-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 84 participants in total. It began in 2016-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pregnancy elicits adaptive changes in uteroplacental blood flow, which are altered at high altitude and may contribute to the observed 3-fold increase in intrauterine growth restriction (IUGR) and preeclampsia (PreE). The investigators propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA). If altered MA vasoreactivity is found, further studies may be able to link these changes to the increased rates of PreE and IUGR at altitude and contribute to the understanding of these two disorders.
Eligibility Criteria
Inclusion Criteria: * Women scheduled for cesarean delivery at University of Colorado Hospital (Denver, 1600 m) and St. Anthony's Summit Medical Center (Summit County, 3000 m) * Cesarean delivery at a prescheduled time without any labor, typically at 39 weeks gestation Exclusion Criteria: * Women will be excluded if there are co-existing medical diagnoses that are known to affect vascular parameters (i.e., diabetes mellitus, gestational diabetes, any hypertensive disorder of pregnancy, or a current smoker). * Women with multiple gestations and preterm deliveries will also be excluded.
Contact & Investigator
Lorna Moore, PhD
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT02391519 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02391519 currently recruiting?
Yes, NCT02391519 is actively recruiting participants. Contact the research team at lorna.moore@ucdenver.edu for enrollment information.
Where is the NCT02391519 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT02391519 clinical trial?
NCT02391519 is sponsored by University of Colorado, Denver. The principal investigator is Lorna Moore, PhD at University of Colorado, Denver. The trial plans to enroll 84 participants.